Understand the source comparison
Mitochondrial Function Peptides vs Receptor-Based Approaches
MOTS-C operates through the mitochondrial genome. Not the nuclear genome. Binding directly to mitochondrial ribosomes to upregulate genes controlling oxidative phosphorylation and fatty acid metabolism. A 2021 study in Cell Metabolism demonstrated MOTS-C admin
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- MOTS-C operates through the mitochondrial genome. Not the nuclear genome. Binding directly to mitochondrial ribosomes to upregulate genes controlling oxidative phosphorylation and fatty acid metabolism. A 2021 study in Cell Metabolism demonstrated MOTS-C administration increased skeletal muscle glucose uptake by 35% and reduced lactate accumulation during sustained exertion. Both biomarkers of improved mitochondrial efficiency. The peptide's 16-amino-acid sequence (mitochondrially encoded) crosses into the mitochondrial matrix without requiring receptor-mediated endocytosis, which eliminates the tolerance curve seen with GH secretagogues.
- Humanin addresses a different node: mitochondrial membrane integrity. Chronic fatigue states consistently show elevated cytochrome c release (a marker of mitochondrial outer membrane permeabilisation), and humanin directly stabilises cardiolipin. The phospholipid that anchors respiratory chain complexes to the inner membrane. Research from USC's Leonard Davis School found humanin analogs reduced oxidative stress markers by 40–50% in aging models where mitochondrial dysfunction drove systemic inflammation. The fatigue-cognition connection matters here: mitochondrial dysfunction in neurons produces the cognitive impairment component of chronic fatigue that purely metabolic interventions miss.
- SS-31 (Elamipretide) takes the most targeted approach. It concentrates specifically in the inner mitochondrial membrane where it scavenges reactive oxygen species at the source. Clinical trials in primary mitochondrial myopathy (published in JAMA Neurology) showed SS-31 improved the six-minute walk test distance by 25 metres vs placebo. A functional measure that correlates with subjective fatigue reduction in patient-reported outcomes. The peptide's tetrapeptide structure allows it to penetrate all tissue types, making it valuable for multi-system fatigue presentations where both skeletal muscle and CNS dysfunction contribute.
- Our experience working with research teams studying these compounds: mitochondrial peptides require longer observation windows than receptor agonists to demonstrate effect, but the improvements don't reverse when dosing stops. A 12-week MOTS-C study we supplied showed sustained ATP production increases measured 8 weeks post-treatment. The mitochondrial adaptations persisted.